UNION therapeutics A/S receives FDA approval for IND of oral next generation PDE4-inhibitor (orismilast) for investigation in plaque psoriasis
· Orismilast is a next generation oral PDE4-inhibitor with an improved therapeutic window compared to other PDE4-inhibitors · Oral orismilast (UNI50001) has demonstrated proof of concept in patients living with plaque psoriasis and indicated “best-in-class” potential · PDE4-inhibition is a validated pharmacological target published for a broad range of inflammatory indications[1] · The improved therapeutic window of orismilast suggests potential for use in a number of inflammatory conditions, which have so far been limited by the typical narrow therapeutic window of PDE4-inhibitors